bpc-157 clinical trials safety human trial evidence fda warning Thinking about trying BPC-157? Read this first. While often marketed as a “healing peptide” BPC-157 is not FDA approved and not pharmacy grade This one means a lot

Potential delay and prevention of age-related diseases

Preclinical Insights Rodent experiments have not shown a consistent rise in serum testosterone after bpc 157 administration

Healing peptides show flexible timing

sustained growth-hormone-axis stimulation also carries a theoretical, class-wide concern for worsened insulin resistance, a recognized effect of excess growth hormone exposure generally Evidence snapshot: The strongest available evidence is a small 1997 randomized, placebo-controlled human trial (19 adults aged 55-71) testing a closely related GHRH(1-29) analog over 16 weeks, which found increased IGF-1 in both sexes, a significant lean-mass increase in men only, and increased skin thickness in both sexes

"Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs"

Krivic, A., Majerovic, M., Jelic, I